不同分子分型青年乳腺癌的臨床特點(diǎn)及預(yù)后因素分析

艾勇彪 袁杰 李文仿

[摘要] 目的 探討35歲及以下不同分子分型乳腺癌患者的臨床病理特點(diǎn)與預(yù)后差異，并分析影響預(yù)后因素。方法 回顧性分析2007年2月～2014年1月湖北省十堰市太和醫(yī)院治療的青年乳腺癌患者（≤35歲）的89例臨床資料，分析其臨床病理特點(diǎn)及預(yù)后影響因素。 結(jié)果 青年乳腺癌患者手術(shù)治療86例，解救性治療3例。手術(shù)患者中Luminal A型21例，Luminal B型16例，HER-2過(guò)表達(dá)型11例，三陰性乳腺癌38例，浸潤(rùn)性導(dǎo)管癌73例，臨床分期Ⅱ期為54.6%和Ⅲ期為24.4%。各分子分型在腫瘤大小、臨床分期、Ki67、淋巴結(jié)轉(zhuǎn)移等指標(biāo)的比較，差異無(wú)統(tǒng)計(jì)學(xué)意義（P > 0.05）。隨訪3年和5年各分子分型的復(fù)發(fā)轉(zhuǎn)移及生存率比較，差異無(wú)統(tǒng)計(jì)學(xué)意義（P > 0.05）。腫瘤大小、淋巴結(jié)轉(zhuǎn)移、Ki67、年齡和臨床分期是影響青年乳腺癌預(yù)后的主要因素（P < 0.05），其中淋巴結(jié)轉(zhuǎn)移、腫瘤大小、臨床分期是影響預(yù)后的獨(dú)立危險(xiǎn)因素（P < 0.05）。 結(jié)論 青年乳腺癌以三陰性患者居多，臨床分期較晚，腫瘤大小與淋巴結(jié)轉(zhuǎn)移對(duì)預(yù)后影響較大，需早診斷早治療，以期提高預(yù)后，但分子分型對(duì)預(yù)后的影響還需進(jìn)一步研究。

[關(guān)鍵詞] 乳腺癌;青年;分子分型;預(yù)后

[中圖分類號(hào)] R737.9? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] A? ? ? ? ? [文章編號(hào)] 1673-7210（2020）03（b）-0117-04

[Abstract] Objective To investigate the clinicopathological characteristics and prognostic differences of patients with different molecular types of breast cancer at the age of 35 and below， and to analyze the prognostic factors. Methods The clinical data of 89 cases of young breast cancer patients （≤35 years old） treated in Taihe Hospital of Shiyan City， Hubei Province from February 2007 to January 2014 were retrospectively analyzed， and the clinicopathological characteristics and prognostic factors were analyzed. Results There were 86 cases of surgical treatment and 3 cases of salvage treatment in young breast cancer patients. Surgery in patients with Luminal A type 21 cases， 16 cases of Luminal B type， HER-2 overexpression was found in 11 cases， triple negative breast cancer 38 cases， invasive ductal carcinoma in 73 cases， clinical staging Ⅱ period 54.6% and Ⅲ period was 24.4%. There was no significant difference in tumor size， clinical stage， Ki67， lymph node metastasis and other indicators in different molecalar types （P > 0.05）. There was no statistically significant difference in recurrence， metastasis and survival rate between 3 and 5 years of follow-up （P > 0.05）. Tumor size， lymph node metastasis， Ki67， age and clinical stage were the main factors influencing the prognosis of young breast cancer （P < 0.05）. Lymph node metastasis， tumor size and clinical stage were independent risk factors for prognosis （P < 0.05）. Conclusions The majority of young breast cancer patients are triple negative， and the clinical stage is late. Tumor size and lymph node metastasis have a great influence on the prognosis， so early diagnosis and early treatment are needed to improve the prognosis. However， the effect of molecular typing on the prognosis needs to be further studied.

[Key words] Breast cancer; Young; Molecular types; Prognosis

[2]? Rapiti E，Pinaud K，Chappuis PO，et al. Opportunities for improving triple-negative breast cancer outcomes：results of a population-based study [J]. Cancer Med，2017，6（3）：526-536.

[3]? 艾勇彪，張丹峰，李文仿，等.青年和老年乳腺癌病理特征及預(yù)后差異的分析[J].現(xiàn)代腫瘤醫(yī)學(xué)，2018，26（23）：3764-3767.

[4]? 劉裔莎，魏兵，楊雯娟，等.美國(guó)癌癥聯(lián)合會(huì)乳腺癌分期（第七版）簡(jiǎn)介[J].中華病理學(xué)雜志，2010，39（11）：787-790.

[5]? 楊文濤，步宏.乳腺癌雌、孕激素受體免疫組織化學(xué)檢測(cè)指南[J].中華病理學(xué)雜志，2015，44（4）：237-239.

[6]? 中國(guó)抗癌協(xié)會(huì)乳腺癌專業(yè)委員會(huì).中國(guó)抗癌協(xié)會(huì)乳腺癌診治指南與規(guī)范（2015版）[J].中國(guó)癌癥雜志，2015，25（9）：692-754.

[7]? 《乳腺癌HER2檢測(cè)指南》編寫組.乳腺癌HER2檢測(cè)指南（2014版）[J].中華病理學(xué)雜志，2014，43（4）：262-267.

[8]? Wang W，Wang X，Liu J，et al. Breast cancer in young women of Chinese Han population：A retrospective study of patients under 25 years [J]. Pathol Res Pract，2016，212（11）：1015-1020.

[9]? Fu J，Wu L，F(xiàn)u W，et al. How young is too young in breast cancer？ -Young breast cancer is not a unique biological subtype [J]. Clin Breast Cancer，2018，18（1）：25-39.

[10]? Botteri E，Veronesi P，Vila J，et al. Improved prognosis of young patients with breast cancer undergoing breast-conserving surgery [J]. Br J Surg，2017，104（13）：1802-1810.

[11]? Lian W，F(xiàn)u F，Lin Y，et al. The Impact of Young Age for Prognosis by Subtype in Women with Early Breast Cancer [J]. Sci Rep，2017，7（1）：11625.

[12]? Alissar EC，Raafat A，Ayman H，et al. Younger age is an independent predictor of worse prognosis among Lebanese nonmetastatic breast cancer patients：analysis of a prospective cohort [J]. Breast Cancer，2017，9（10）：407-414.

[13]? Ellsworth RE，Blackburn HL，Shriver CD，et al. Molecular heterogeneity in breast cancer：State of the science and implications for patient care [J]. Semin Cell Dev Biol，2017，64（1）：65-72.

[14]? Roulot A，Héquet D，Guinebretière JM，et al. Tumoral heterogeneity of breast cancer [J]. Ann Biol Clin，2016， 74（6）：653-660.

[15]? Esparza-López J，Escobar-Arriaga E，Soto-Germes S，et al. Breast Cancer Intra-Tumor Heterogeneity：One Tumor，Different Entities [J]. Rev Invest Clin，2017，69（2）：66-76.

[16]? Munoz DF，Plevritis SK. Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment [J]. Med Decis Making，2018，38（1）：32-43.

[17]? Plevritis SK，Munoz D，Kurian AW，et al. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women，2000-2012 [J]. JAMA，2018，319（2）：154-164.

[18]? Alabdulkareem H，Pinchinat T，Khan S，et al. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy [J]. Breast J，2018，24（2）：148-153.

[19]? Adriana-Andreea J，Maria CA，Domenico R，et al. Triple negative breast cancer：the kiss of death [J]. Oncotarget，2017，8（28）：46652-46662.

[20]? Maishman T，Cutress RI，Hernandez A，et al. Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer [J]. Ann Surg，2017，266（1）：165-172.

[21]? 宋美英，王玲，張財(cái)家，等.對(duì)比分析青年及中老年乳腺癌患者臨床病理特征及免疫組化特點(diǎn)[J].當(dāng)代醫(yī)學(xué)，2019，25（28）：80-82.

[22]? Ellegaard MBB，Grau C，Zachariae R，et al. Fear of cancer recurrence and unmet needs among breast cancer survivors in the first five years. A cross-sectional study [J]. Acta Oncol，2017，56（2）：314-320.

[23]? Liedtke C，Rody A，Gluz O，Baumann K，et al. The prognostic impact of age in different molecular subtypes of breast cancer [J]. Breast Cancer Res Treat，2015，152（3）：667-673.

[24]? Gregorio DI，F(xiàn)ord C，Samociuk H. Geography of breast cancer incidence according to age & birth cohorts [J]. Spat Spatiotemporal Epidemiol，2017，21（3）：47-55.

[25]? Wen D，Wen X，Yang Y，et al. Urban rural disparity in female breast cancer incidence rate in China and the increasing trend in parallel with socioeconomic development and urbanization in a rural setting [J]. Thorac Cancer，2018，9（2）：262-272.

[26]? 韋玉亞，姜偉，朱婷，等.X線和彩色多普勒超聲成像在早期乳腺癌診斷中的價(jià)值[J].中國(guó)醫(yī)藥科學(xué)，2019，9（13）：160-163.

（收稿日期：2019-07-02? 本文編輯：封? ?華）